{
    "eid": "2-s2.0-85129283276",
    "title": "Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation",
    "cover-date": "2022-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Daratumumab",
        "Major ABO-mismatched",
        "Pure red cell aplasia"
    ],
    "authors": [
        "Thiti Asawapanumas",
        "Chantiya Chanswangphuwana",
        "Phandee Watanaboonyongcharoen",
        "Ponlapat Rojnuckarin",
        "Udomsak Bunworasate"
    ],
    "citedby-count": 4,
    "ref-count": 15,
    "ref-list": [
        "Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation",
        "Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation",
        "Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia",
        "Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion",
        "Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib",
        "Ayad Hamdan. Pure Red Cell Aplasia after ABO-Mismatched Allogeneic Stem Cell Transplantation Treated with Therapeutic Plasma Exchange and Rituximab",
        "Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation",
        "Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab",
        "Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation",
        "Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation",
        "Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab",
        "Different prognostic effects of core-binding factor positive AML with Korean AML registry data",
        "Resolving the daratumumab interference with blood compatibility testing",
        "Blood Transfusion Management for Patients Treated with Anti-CD38 Monoclonal Antibodies",
        "Daratumumab rapidly reduces high-titre factor VIII inhibitors in haemophilia A patients during life-threatening haemorrhages"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Janssen-Cilag (Thailand) Ltd"
    ]
}